All studies
Immunology · Registry · UK, Ireland
Yiu 2021
Psoriasis
PPSuperiorityAcademic2/5 disclosures
Comparisons
2
In the analysis
0
2 withheld
Target trials
1
Emulations reported
5
2 treatments
Design and methods
- Estimand
- PP
- Design hypothesis
- Superiority
- Matching / weighting
- 1:1 PS matching, IPTW
- Analysis method
- Generalized linear models with a log link (RR), with an identity link (RD)
- Missing data
- Complete case, Nonresponder imputation, LOCF, IPCW, Multiple imputation
- Covariates adjusted
- 18
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Registry
- Data sources
- 1
- Geography
- UK, Ireland
- Eligible sample
- 1231
- Treated
- 314
- Control
- 917
- Emulations
- 5
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- AbbVie, Almirall, Amgen, Arena, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, Samsung Bioepis, Sandoz Hexal AG, UCB Pharma Ltd
- Funding
- Declared: Public, professional society, private
- Funders
- NIHR Manchester Biomedical Research Centre, NIHR Newcastle Biomedical Research Centre
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2021_Yiu_Psoriasis
- DOI
- https://doi.org/10.1001/jamadermatol.2020.4202
- Affiliations
- University of Manchester, Newcastle University Medical School, Newcastle Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Salford Royal NHS Foundation Trust
- Sector
- Academic
- Target trials (study level)
- CLEAR
- Registration
- NCT02074982